GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Nanoform Finland PLC (OSTO:NANOFS) » Definitions » GF Score

Nanoform Finland (OSTO:NANOFS) GF Score : 54/100 (As of May. 26, 2024)


View and export this data going back to 2020. Start your Free Trial

What is Nanoform Finland GF Score?

Nanoform Finland has the GF Score of 54, which implies that the company might have Poor future performance potential.

The GF Score is a stock performance ranking system developed by GuruFocus using five aspects of valuation, which has been found to be closely correlated to the long-term performances of stocks by backtesting from 2006 to 2021. The stocks with a higher GF Score generally generate higher returns than those with lower GF Scores. Therefore, when picking stocks, investors should invest in companies with high GF Scores. The GF Score ranges from 0 to 100, with 100 as the highest rank.

GF Score takes following five key aspects into consideration:

1. Financial Strength : 6/10
2. Profitability Rank : 3/10
3. Growth Rank : 5/10
4. GF Value Rank : 8/10
5. Momentum Rank : 0/10

Each one of these components is ranked and the ranks also have positive correlation with the long term performances of stocks. The GF score is calculated using the five key aspects of analysis. Through backtesting, we know that each of these key aspects has a different impact on the stock price performance. Thus, they are weighted differently when calculating the total score. The Profitability Rank and the Growth Rank are weighted fully, while other parameters have less weight.

Based on research and backtesting result, GuruFocus believes Nanoform Finland might have Poor future performance potential.

Please click GF Score to see more details on the GF Score's 5 Key Aspects of Analysis.


Competitive Comparison of Nanoform Finland's GF Score

For the Biotechnology subindustry, Nanoform Finland's GF Score, along with its competitors' market caps and GF Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Nanoform Finland's GF Score Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Nanoform Finland's GF Score distribution charts can be found below:

* The bar in red indicates where Nanoform Finland's GF Score falls into.



Nanoform Finland  (OSTO:NANOFS) GF Score Explanation

Based on the historical long-term performances among five valuation aspects, the GF Score is found to be closely correlated to the long-term performances of stocks. It ranges from 0 to 100, with 100 as the highest. GuruFocus divided GF Score into following 5 categories:

GF Score Performance Potential and All-in-One Screener Examples (1)
91 - 100Highest outperformance potential
81 - 90Good outperformance potential
71 - 80Likely to have average performance
51 - 70Poor future performance potential
0 - 50Worst future performance potential, or not enough data

(1) These are some simple examples. You can access our GF Score filter under All-in-One Screener’s Fundamental tab.


Nanoform Finland GF Score Related Terms

Thank you for viewing the detailed overview of Nanoform Finland's GF Score provided by GuruFocus.com. Please click on the following links to see related term pages.


Nanoform Finland (OSTO:NANOFS) Business Description

Traded in Other Exchanges
Address
Cultivator II, Viikinkaari 4, Helsinki, FIN, 00790
Nanoform Finland PLC is a nanoparticle medicine-enabling company. The company works together with pharma and biotech partners to reduce attrition in clinical trials and enhance their molecules' formulation performance through its nano-forming services. Its patented and scalable Controlled Expansion of Supercritical Solutions (CESS) technology produces nano-formed API particles as small as 10nm. This enables poorly soluble molecules in the pharmaceutical pipeline to progress into clinical development by increasing their rate of dissolution and by improving their bioavailability. Its technology provides novel opportunities in many value-enhancing drug delivery applications.

Nanoform Finland (OSTO:NANOFS) Headlines

No Headlines